American Association for Cancer Research
21598290cd110336-sup-f5_71k.pdf (71.03 kB)

Supplementary Figure 5 from Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Download (71.03 kB)
journal contribution
posted on 2023-04-03, 20:26 authored by Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf

PDF file - 71K, Standard Curve for the quantitation of NVP-BKM120 in tumor cell lysates. Counts were measured from the peaks of the total ion current for NVP-BKM-120, integrated using MultiQuant v2.0 software (AB/SCIEX). For the concentration curve data, BKM-120 was prepared at concentrations of 1 nM, 10 nM, 100 nM, 500 nM, 1 muM and 10 muM in 40% methanol



There is a need to improve treatments for metastatic breast cancer. Here, we show the activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in a MMTV-CreBrca1f/fTrp53+/− mouse model of breast cancer. When treated with the pan-class IA PI3K inhibitor NVP-BKM120, tumor doubling was delayed from 5 to 26 days. NVP-BKM120 reduced AKT phosphorylation, tumor cell proliferation, and angiogenesis. Resistant tumors maintained suppression of AKT phosphorylation but exhibited activation of the MAPK pathway at the “pushing margin.” Surprisingly, PI3K inhibition increased indicators of DNA damage, poly-ADP-ribosylation (PAR), and γ-H2AX, but decreased Rad51 focus formation, suggesting a critical role of PI3K activity for Rad51 recruitment. The PARP inhibitor olaparib alone attenuated tumor growth modestly; however, the combination of NVP-BKM120 and olaparib delayed tumor doubling to more than 70 days in the mouse model and more than 50 days in xenotransplants from human BRCA1-related tumors, suggesting that combined PI3K and PARP inhibition might be an effective treatment of BRCA1-related tumors.Significance: Current treatment options for triple-negative breast cancer are limited to chemotherapeutic regimens that have considerable toxicity and are not curative. We report here that the combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials. Cancer Discov; 2(11); 1048–63. ©2012 AACR.Read the Commentary on this article by Rehman et al., p. 982.This article is highlighted in the In This Issue feature, p. 961

Usage metrics

    Cancer Discovery



    Ref. manager